NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 75 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $128.78 million which beat the analyst consensus estimate of $121.54 million by 5.96 percent. This is a 6.13 percent increase over sales of $121.34 million the same period last year.
Rare Disease Player BridgeBio Pharma Draws Attention Of Big Pharma Companies, Gets Takeover Interest
BridgeBio Pharma Inc (NASDAQ: BBIO) is reportedly attracting takeover interest as some large pharmaceutical companies are studying a potential acquisition of the biotech firm.
